PM4

PM4 (PF3D7_1407800) is a food-vacuole aspartic protease that initiates and drives the intraerythrocytic hemoglobin degradation pathway of Plasmodium and thereby feeds hemozoin formation (PMID:11782538, PMID:11904142). It is expressed during the hemoglobin-degrading blood stage and localizes to the food vacuole, where it acts as one of four active hemoglobinase plasmepsins in P. falciparum (with PM1, PM2, and HAP) but is the sole food-vacuole plasmepsin in other Plasmodium species (PMID:11782538, PMID:14550891). Recombinant PM4 hydrolyzes native and denatured hemoglobin, including cleavage at the site that initiates hemoglobin catabolism, and its activity is blocked by peptidomimetic inhibitors that also arrest parasite growth (PMID:11904142, PMID:21334328). PM4 is synthesized as a zymogen that undergoes acid-triggered maturation: vacuolar plasmepsin pro-forms assemble into S-shaped dimers, and under acidic pH conformational changes at the Tyr-Asp loop, loop L1, and helix H2 dissociate the dimer and expose the cleavage site so that one monomer trans-activates the prosegment of the other (PMID:32385863, PMID:27599854). Once mature, PM4 operates within an ~200-kDa food-vacuole complex containing falcipain 2/2', PM2, HAP, and the heme detoxification protein HDP that couples hemoglobin proteolysis to hemozoin formation (PMID:23471987). Genetic disruption studies establish PM4 as functionally important but non-essential: Δpfpm4 parasites grow more slowly and, among the single food-vacuole plasmepsin knockouts, show the greatest reduction in hemozoin accumulation without compensatory paralog upregulation (PMID:15491999, PMID:17207486). In P. berghei, pm4 deletion attenuates blood-stage growth and prevents experimental cerebral malaria while conferring protective immunity (PMID:20019192), and in the avian parasite P. gallinaceum the PM4 ortholog additionally localizes to ookinete micronemes and the apical surface and participates in mosquito midgut invasion (PMID:20056606).

1. 2002 High

   Establishing where PM4 acts and what it does answered whether it is a bona fide hemoglobinase rather than merely a plasmepsin family member.

   Evidence Genome-wide expression, food-vacuole fractionation, and enzymatic assays in P. falciparum, plus recombinant hemoglobin hydrolysis and inhibitor assays

   PMID:11782538 PMID:11904142

   Open questions at the time

   • Relative contribution of PM4 versus the other three vacuolar plasmepsins not yet quantified
   • In vivo cleavage kinetics on intact hemoglobin within the vacuole not resolved
2. 2003 High

   Cross-species localization defined PM4 as the conserved core food-vacuole plasmepsin, showing that non-falciparum species rely on PM4 alone whereas P. falciparum has paralog redundancy.

   Evidence 2D gel electrophoresis and mass spectrometry of purified food-vacuole fractions across seven Plasmodium species; genomic DNA blot

   PMID:14550891

   Open questions at the time

   • Functional consequence of single- versus multi-plasmepsin architecture not tested here
   • Does not address complex membership or maturation
3. 2004 High

   Gene disruption tested whether PM4 is essential and revealed a specific hemoglobin-digestion phenotype rather than lethality.

   Evidence Homologous-recombination knockout in P. falciparum Dd2 with growth, hemozoin, and EM readouts

   PMID:15491999

   Open questions at the time

   • Cannot exclude partial compensation by paralogs
   • Molecular basis of the electron-dense vesicle accumulation unresolved
4. 2006 High

   Comparing single- and quadruple-knockouts ranked PM4 as the dominant individual vacuolar plasmepsin for hemozoin production and showed the ensemble also processes endosomal cargo.

   Evidence Single and quadruple plasmepsin knockouts in P. falciparum with hemozoin quantification, Northern/Western for paralogs, EM and autophagic markers

   PMID:17207486 PMID:17581121

   Open questions at the time

   • Mechanism by which PM4 loss reduces hemozoin more than other paralogs not defined
   • No compensatory upregulation seen, but functional overlap during infection not measured
5. 2006 Medium

   Structural and inhibitor-binding characterization began to define PM4's active-site geometry and the features distinguishing it from PM2 for selective drug design.

   Evidence Crystal structure/homology model with molecular dynamics, LIE calculations, and in vitro Ki measurements

   PMID:12859191 PMID:16939205

   Open questions at the time

   • Relied partly on homology modeling rather than de novo PM4 structure
   • Selectivity over host aspartic proteases not established here
6. 2010 Medium

   Discovery of a secreted, apically localized PM4 in ookinetes extended its role beyond the food vacuole to mosquito-stage invasion.

   Evidence De novo MS sequencing, immunolocalization, and infectivity blockade with monoclonal antibodies and inhibitors in P. gallinaceum

   PMID:20056606

   Open questions at the time

   • Shown in P. gallinaceum, not P. falciparum
   • Molecular substrate mediating midgut invasion not identified
7. 2011 High

   Reconstitution of recombinant PM4 established acid-triggered autocatalytic maturation and cooperative hemoglobin digestion with cysteine proteases.

   Evidence Recombinant expression, refolding, autocatalytic maturation, hemoglobin hydrolysis, and synergy assays with vivapains in P. vivax

   PMID:21334328

   Open questions at the time

   • Structural intermediate of maturation not resolved in this study
   • In vivo relevance of vivapain-mediated PM4 processing not tested
8. 2011 Medium

   Genetic epistasis with msp7 in P. berghei defined PM4 as a virulence determinant whose loss can be combined to attenuate infection and elicit cross-protective immunity.

   Evidence Sequential gene disruption, in vivo parasitemia monitoring, and cross-species challenge in P. berghei

   PMID:20019192 PMID:22355558

   Open questions at the time

   • Mechanistic link between PM4 loss and reduced virulence not molecularly defined
   • Single-lab in vivo studies
9. 2015 High

   Active-site subsite mapping and a high-resolution zymogen structure provided the biochemical and structural framework for selective PM4 inhibition.

   Evidence Combinatorial peptide-library profiling and inhibitor design in P. berghei; 1.5 Å crystal structure of the P. falciparum truncated zymogen

   PMID:26510189 PMID:27599854

   Open questions at the time

   • Structure is of the zymogen; mature-enzyme substrate complex not captured
   • Selectivity data are in vitro
10. 2018 Medium

    Inhibitor and drug-repurposing studies linked PM4 to the antimalarial action of specific protease inhibitors, supporting it as a druggable target.

    Evidence Low-nanomolar KNI Ki measurements with PMII-KNI crystal surrogates in P. falciparum, and pm4 knockout drug-sensitivity tests with docking in P. berghei ANKA

    PMID:29943906 PMID:30067811

    Open questions at the time

    • PMIV inhibitor complexes not independently solved
    • Contribution of PM4 to lopinavir/saquinavir action only inferred from KO sensitivity
11. 2020 High

    Solving the activation mechanism explained how PM4 converts from inactive zymogen to mature protease under acidic vacuolar conditions.

    Evidence Multiple crystal structures, MD simulations, and biochemical activation assays defining S-shaped dimer trans-activation in P. falciparum

    PMID:32385863

    Open questions at the time

    • Whether trans-activation occurs identically in the intact vacuolar complex not shown
    • Regulation of activation timing in vivo not addressed

• How PM4's individual proteolytic activity is coordinated within the ~200-kDa vacuolar complex and how its blood-stage role relates mechanistically to its mosquito-stage invasion function remain unresolved.
• Stoichiometry and regulatory role of PM4 within the hemoglobinase complex undefined
• Molecular substrates in ookinete midgut invasion unknown
• Direct connection between hemoglobin digestion and virulence/ECM not mechanistically established